Free Trial

Roivant Sciences Q3 2025 Earnings Report

Roivant Sciences logo
$9.46 -0.55 (-5.49%)
As of 04/4/2025 04:00 PM Eastern

Roivant Sciences EPS Results

Actual EPS
-$0.20
Consensus EPS
-$0.24
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Roivant Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
$4.75 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Roivant Sciences Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Remove Ads

Roivant Sciences Earnings Headlines

Is the Biotech Sector Oversaturated?
America’s Retirement Accounts Are at Risk—Here’s Why
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
See More Roivant Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Roivant Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Roivant Sciences and other key companies, straight to your email.

About Roivant Sciences

Roivant Sciences (NASDAQ:ROIV), a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

View Roivant Sciences Profile

More Earnings Resources from MarketBeat